| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.4 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |